{"id":"NCT01416441","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","briefTitle":"Safety and Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder","officialTitle":"An Open-Label, Multicenter Study Evaluating the Safety and Tolerability of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-10-19","primaryCompletion":"2014-03-13","completion":"2014-03-13","firstPosted":"2011-08-15","resultsPosted":"2021-10-07","lastUpdate":"2021-10-07"},"enrollment":170,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Tourette's Disorder"],"interventions":[{"type":"DRUG","name":"Aripiprazole","otherNames":["ABILIFY"]}],"arms":[{"label":"Aripiprazole","type":"EXPERIMENTAL"}],"summary":"The goal of the current trial is to obtain long term efficacy, safety and tolerability data of once weekly aripiprazole in children and adolescents with Tourette's Disorder.","primaryOutcome":{"measure":"Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Severe TEAEs and TEAEs Leading Treatment Discontinuation","timeFrame":"From signing of the informed consent up to 30 days after the last dose (Up to Week 52)","effectByArm":[{"arm":"Aripiprazole (Once Weekly)","deltaMin":5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"7 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":7},"locations":{"siteCount":80,"countries":["United States","Bulgaria","Canada","Germany","Hungary","Mexico","Romania","South Korea","Taiwan","Ukraine"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":170},"commonTop":["Headache","Weight increased","Vomiting","Nasopharyngitis","Upper respiratory tract infection"]}}